ATOM: A Phase II Study to Assess Efficacy of Preemptive Local Ablative Therapy to Residual Oligometastases of NSCLC After EGFR TKI

Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKI) are highly effective treatment in metastatic non-small cell lung cancer (NSCLC). However the median progression free survival (PFS) lasts 9-13 months [1 –2]. Recently, studies demonstrated that second and third generation TKIs dacomitinib and osimertinib can both achieve a longer PFS compared to 1st generation TKIs [3–4]. Nevertheless, access to both agents is still limited in many countries due to the affordability and registration process.

Source: Lung Cancer - February 10, 2020 Category: Cancer & Oncology Authors: Oscar S.H. Chan, Kwok Chi Lam, Jacky Y.C. Li, Frankie P.T. Choi, Catherine Y.H. Wong, Amy T.Y. Chang, Frankie Mo, Ki Wang, Rebecca M.W. Yeung, Tony S.K. Mok Source Type: research